초록 ▼

An anti-viral compounds effective against viruses belonging to the Flaviviridae family, wherein the anti-viral compounds are 1,5-dideoxy-1,5-imino-D-glucitol derivative compounds having the general formula (I) wherein R2, R3, R4 and R5 are the same or different and are selected from the group consi

An anti-viral compounds effective against viruses belonging to the Flaviviridae family, wherein the anti-viral compounds are 1,5-dideoxy-1,5-imino-D-glucitol derivative compounds having the general formula (I) wherein R2, R3, R4 and R5 are the same or different and are selected from the group consisting of hydrogen, acyl, benzyl, alkyl, aryl, sulfonyl, phosphonyl, silyl, R6 is at least one of alkyl or branched alkyl, heteroalkyl or aryl, R6′ is a bridging group selected from at least one of bicycle2.2.1heptyl, bicycle3.2.1octyl, oxa analogs, admonyl and cubyl, n′=2-10, n″=1-10, enantiomers and stereoisomers of said compounds and physiologically acceptable salts or solvates of said compounds, enantiomer or stereoisomer.

대표청구항 ▼

1. A 1,5-dideoxy-1,5-imino-D-glucitol derivative compound having the general formula (I) wherein R2, R3, R4 and R5 are the same or different and are selected from the group consisting of hydrogen, acyl, benzyl, alkyl, aryl, sulfonyl, phosphonyl, silyl, R6 is at least one of alkyl or branched alkyl,

1. A 1,5-dideoxy-1,5-imino-D-glucitol derivative compound having the general formula (I) wherein R2, R3, R4 and R5 are the same or different and are selected from the group consisting of hydrogen, acyl, benzyl, alkyl, aryl, sulfonyl, phosphonyl, silyl, R6 is at least one of alkyl or branched alkyl, heteroalkyl, hydrogen, or aryl,R6′ is hydrogen,n′=2-10,n″=4-6or an enantiomers or stereoisomer of said compound and physiologically acceptable salts of said compound, enantiomer or stereoisomer. 2. The compound of claim 1, wherein n′ is 4, 5, or 6. 3. The compound of claim 1, wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-pentyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (III): 4. The compound of claim 1, wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-butyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (IV): 5. The compound of claim 1, wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-hexyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (V): 6. An anti-viral composition comprising a 1,5-dideoxy-1,5-imino-D-glucitol derivative compound having the general formula (I) wherein R2, R3, R4 and R5 are the same or different and are selected from the group consisting of hydrogen, acyl, benzyl, alkyl, aryl, sulfonyl, phosphonyl, silyl,R6 is at least one of alkyl or branched alkyl, heteroalkyl, hydrogen, or aryl,R6′ is hydrogen,n′=2-10,n″=4-6,or an enantiomers or stereoisomer of said compound and physiologically acceptable salts of said compound, enantiomer or stereoisomer. 7. The anti-viral compound of claim 6, wherein n′ is 4, 5, or 6. 8. A method for inhibiting production of a virus belonging to the Flaviviridae family comprising contacting a mammalian cell infected by said virus with an effective amount of an anti-viral composition comprising the anti-viral compound of claim 6. 9. The method of claim 8, wherein in the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound, R7 is a C4-C6 alkyl moiety. 10. The method of claim 8, wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-pentyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (III): 11. The method of claim 8, wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-butyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (IV): 12. The method of claim 8, wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-hexyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (V): 13. The method of claim 8, wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound, enantiomer, or stereoisomer, or physiologically acceptable salt of said compound, enantiomer, or stereoisomer is administered to a mammal. 14. The method of claim 8, wherein the 1,5-dideoxy-1,5-imino-D-gucitol derivative compound, enantiomer, or stereoisomer, or physiologically acceptable salt of said compound, enantiomer, or stereoisomer is administered to a human. 15. The method of claim 8, wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound, enantiomer, or stereoisomer, or physiologically acceptable salt of said compound, enantiomer, or stereoisomer is administered to said mammalian cell in vivo. 16. The method of claim 8, wherein said virus is at least one of West Nile fever virus, dengue virus, bovine viral diarrhea virus, and hepatitis B virus. 17. The method of claim 11, wherein said virus is a flavivirus. 18. The method of claim 17, wherein the flavivirus is selected from the group consisting of yellow fever virus, Japanese encephalitis virus, Murray Valley encephalitis, Rocio virus, St. Louis encephalitis virus, tick-borne encephalitis virus, Louping ill virus, Powassan virus, Omsk hemorrhagic fever virus and Kyasanur forest disease virus. 19. The method of claim 17, said virus is a pestivirus. 20. The method of claim 17, said virus is at least one of bovine diarrhea virus or hepatitis C virus.